On Feb 3, 2022 Dewpoint Therapeutics closed a Series C round and raised $150,000,000 from 3E Bioventures, ARCH Venture Partners, EcoR1 Capital, General Catalyst, Leaps by Bayer, Maverick Ventures, Mirae Asset Capital, Mubadala Capital Ventures, NS Investment, Polaris Partners, Samsara BioCapital, SoftBank Vision Fund, featuring lead investors SoftBank Vision Fund.

About the company: Dewpoint Therapeutics is located at United States, North America.
“At Dewpoint, we translate condensate biology into much-needed medicines. Condensates play a critical role in a wide range of important diseases.”

Company website: http://www.dewpointx.com